NITROGLYCERIN IN DEXTROSE
According to the FDA label: INDICATIONS & USAGE Nitroglycerin in 5% Dextrose Injection is indicated for treatment of peri-operative hypertension; for control of heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and ß-blockers; and for induction of intraoperative hypotension.
39,097 adverse event reports submitted to the FDA (1999–2026)
Top Reported Adverse Events
The most frequently reported events in association with NITROGLYCERIN IN DEXTROSE in the FAERS database. These are events reported by patients taking this medication — not necessarily caused by it. A single report may include multiple events.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
By Age Group
Reported Outcomes
Outcomes recorded in FAERS reports that included NITROGLYCERIN IN DEXTROSE. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
Report Volume Over Time
Number of FAERS reports received per quarter for NITROGLYCERIN IN DEXTROSE. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior — not changes in the medication's safety profile.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA Adverse Event Reporting System (FAERS) via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →